[1]李梦歌,苏恒.开源人工胰腺在1型糖尿病中的应用[J].国际内分泌代谢杂志,2022,42(05):369-372.[doi:10.3760/cma.j.cn121383-20210304-03012]
　Li Mengge,Su Heng..Application of Do-it-yourself artificial pancreas in type 1 diabetes[J].International Journal of Endocrinology and Metabolism,2022,42(05):369-372.[doi:10.3760/cma.j.cn121383-20210304-03012]
点击复制

开源人工胰腺在1型糖尿病中的应用()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
369-372
栏目:
综述
出版日期:
2022-09-20

文章信息/Info

Title:
Application of Do-it-yourself artificial pancreas in type 1 diabetes
作者:
李梦歌1; 2; 苏恒1
1昆明理工大学医学院 650500; 2昆明理工大学附属医院,云南省第一人民医院内分泌代谢科 650032
Author(s):
Li Mengge1; 2;  Su Heng2.
1Medical School, Kunming University of Science and Technology, Kunming 650500, China; 2Department of Endocrinology, the First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, China
关键词:
开源人工胰腺;  闭环;  1型糖尿病;  胰岛素治疗
Keywords:
Do-it-yourself artificial pancreas;  Loop;  Type 1 diabetes mellitus;  Insulin treatment
DOI:
10.3760/cma.j.cn121383-20210304-03012
摘要:
1型糖尿病(T1DM)需要终身胰岛素替代治疗。近年来,胰岛素制剂和给药方式领域的研究进展为T1DM的治疗提供了有力的手段,但在模拟生理性胰岛素分泌的给药方式方面仍面临多重挑战。整合新一代血糖传感器、胰岛素泵及商用混合闭环系统等技术的开源人工胰腺(Do-it-yourself artificial pancreas,DIYAPS)为T1DM的血糖管理提供了新的思路和方案。本文对DIYAPS的起源、类型、临床证据、优缺点以及应用前景进行了综述,以帮助临床医生和患者更好地利用这些系统。
Abstract:
People with Type 1 diabetes mellitus(T1DM)require life-long insulin replacement therapy. The research progress of insulin preparations and administration methods have provided a powerful tool for the treatment of T1DM in recent years, but there are still multiple challenges in simulating physiological insulin secretion. The Do-it-yourself artificial pancreas(DIYAPS)that integrates the technologies of a new generation of blood glucose sensors, insulin pumps and commercial hybrid closed-loop systems, provides new ideas and solutions for the blood glucose management of T1DM. Here we provide a description of the DIYAPS-including their origin, clinical evidence, advantages, and disadvantages that can help clinicians and patients to make the best use of these systems.

参考文献/References:

[1] Chiang JL,Kirkman MS,Laffel LM,et al.Type 1 Diabetes Through the Life Span:A Position Statement of the American Diabetes Association[J].Diabetes Care,2014,37(7):2034-2054.DOI:10.2337/dc14-1140.
[2] Alcántara-Aragón V.Improving patient self-care using diabetes technologies[J].Ther Adv Endocrinol Metab,2019,10:2042018818824215.DOI:10.1177/2042018818824215.
[3] Omer T.Empowered citizen 'health hackers' who are not waiting[J].BMC Med,2016,14(1):118.DOI:10.1186/s12916-016-0670-y.
[4] Lewis DM.Do-It-Yourself artificial pancreas system and the OpenAPS movement[J].Endocrinol Metab Clin North Am,2020,49(1):203-213.DOI:10.1016/j.ecl.2019.10.005.
[5] Kesavadev J,Srinivasan S,Saboo B,et al.The Do-It-Yourself artificial pancreas:s comprehensive review[J].Diabetes Ther,2020,11(6):1217-1235.DOI:10.1007/s13300-020-00823-z.
[6] Heinemann L,Lange K."Do It Yourself"(DIY)-Automated Insulin Delivery(AID)systems:current status from a German point of view[J].J Diabetes Sci Technol,2020,14(6):1028-1034.DOI:10.1177/1932296819889641.
[7] Horowitz ME,Kaye WA,Pepper GM,et al.An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control,quality of life,and compliance[J].Diabetes Res Clin Pract,2021,177:108876.DOI:10.1016/j.diabres.2021.108876.
[8] Berget C,Akturk HK,Messer LH,et al.Real-world performance of hybrid closed loop in youth,young adults,adults and older adults with type 1 diabetes:Identifying a clinical target for hybrid closed-loop use[J].Diabetes Obes Metab.2021,23(9):2048-2057.DOI:10.1111/dom.14441.
[9] Lewis DM,Swain RS,Donner TW.Improvements in A1C and Time-in-Range in DIY Closed-Loop(OpenAPS)users[J].Diabetes,2018,67(Supplement 1):352-OR.DOI:10.2337/db18-352-OR.
[10] Melmer A,Züger T,Lewis DM,et al.Glycemic control in individuals with type 1 diabetes using an open source artificial pancreas system(OpenAPS)[J].Diabetes Obesity and Metabolism,2019,21(10):2333-2337.DOI:10.1111/dom.13810.
[11] Gawrecki A,Zozulinska-Ziolkiewicz D,Michalak MA,et al.Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes[J].PLoS One,2021,16(4):e0248965.DOI:10.1371/journal.pone.0248965.
[12] Braune K,O'Donnell S,Cleal B,et al.Real-World use of do-it-yourself artificial pancreas systems in children and adolescents:self-reported clinical outcomes[J].JMIR Mhealth Uhealth,2019,7(7):e14087.DOI:10.2196/14087.
[13] Choi SB,Hong ES,Noh YH.Open Artificial pancreas system reduced hypoglycemia and improved glycemic control in patients with type 1 diabetes[J].Diabetes,2018,67(Supplement 1):964-P.DOI:10.2337/db18-964-P.
[14] Jeyaventhan R,Gallen G,Choudhary P,et al.A real-world study of user characteristics,safety and efficacy of open-source closed-loop systems and medtronic 670G[J].Diabetes Obes Metab,2021,23(8):1989-1994.DOI:10.1111/dom.14439.
[15] Bazdarska Y,Iotova V,Mladenov V,et al.Advantages from "do-it-yourself" loops among children and adolescents in Varna's Diabetes Center[J].Scripta Scientica Medica,2020,52(1):12-19.DOI:10.14748/ssm.v51i3.6515.
[16] Petruzelkova L,Soupal J,Plasova V,et al.Excellent glycemic control maintained by open-source hybrid closed-loop androidAPS during and after sustained physical activity[J].Diabetes Technol Ther,2018,20(11):744-750.DOI:10.1089/dia.2018.0214.
[17] Foerster V,Severn M.A Hybrid Closed-Loop insulin delivery system for the treatment of type 1 diabetes[J].CADTH Issues in Emerging Health Technologies,2017,1-11.
[18] Braune K,O'Donnell S,Cleal B,et al.Factors influencing motivation,barriers,and duration of DIY artificial pancreas system use among real-world users[J].Diabetes,2019,68(Supplement 1):117-LB.DOI:10.2337/db19-117-LB.
[19] Farrington C.Hacking diabetes:DIY artificial pancreas systems[J].Lancet Diabetes Endocrinol,2017,5(5):332.DOI:10.1016/S2213-8587(16)30397-7.
[20] Ahmed Mohamed I,Fisher A,Cooper P,et al.Use of continuous glucose monitoring in people with type 1 diabetes:perspectives of two people with diabetes and physician perspective[J].Diabetes Ther,2019,10(2):333-340.DOI:10.1007/s13300-019-0576-8.
[21] Marshall DC,Holloway M,Korer M,et al.Do-It-Yourself artificial pancreas systems in type 1 diabetes:perspectives of two adult users,a caregiver and three physicians[J].Diabetes Ther,2019,10(5):1553-1564.DOI:10.1007/s13300-019-00679-y.
[22] Oliver N,Reddy M,Marriott C,et al.Open source automated insulin delivery:addressing the challenge[J].NPJ Digit Med,2019,2:124.DOI:10.1038/s41746-019-0202-1.
[23] de Bock M.The "do it yourself" type 1 diabetes dilemma for medical practitioners[J].Intern Med J,2019,49(5):559-561.DOI:10.1111/imj.14286.
[24] Crabtree TS,Mclay A,Wilmot EG.DIY artificial pancreas systems:here to stay?[J].Practical Diabetes,2019,36(2):63-68.DOI:10.1002/pdi.2216.
[25] O'Donnell S,Lewis D,Marchante Fernández M,et al.Evidence on User Led Innovation in Diabetes Technology(The OPEN Project):Protocol for a Mixed Methods Study[J].JMIR Res Protoc,2019,8(11):e15368.DOI:10.2196/15368.

备注/Memo

备注/Memo:
通信作者:苏恒,Email:su_hen@hotmail.com
更新日期/Last Update: 2022-09-10